Physician profile
Chase Bennett Wight
NPI 1215446331
$5,934.76
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,037 · 2022: $2,910 · 2023: $1,960 · 2024: $28.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,988.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $663.63 | 2021-2024 | |
| Nevro Corp. | $542.28 | 2021-2022 | |
| Lundbeck LLC | $457.02 | 2021-2023 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $344.16 | 2021-2023 | Ajovy |
| Ucb, INC. | $315.28 | 2021-2023 | Briviact |
| Scilex Pharmaceuticals INC. | $285.36 | 2022-2023 | Ztlido |
| Amgen INC. | $278.83 | 2021-2023 | Aimovig |
| Collegium Pharmaceutical, INC. | $268.91 | 2021-2023 | Belbuca |
| Sk Life Science, INC. | $225.52 | 2021-2023 | |
| Grifols USA, LLC | $208.50 | 2022-2023 | Gamunex-C |
| Lilly USA, LLC | $185.12 | 2021-2023 | Emgality |
| Biogen, INC. | $173.12 | 2021-2022 | |
| Almatica Pharma LLC | $171.78 | 2022-2023 | Gralise |
| Biohaven Pharmaceutical Holding Company LTD. | $140.99 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.22 | 2022-2023 | Relistor |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chase Wight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.